Epcoritamab (GEN3013; DuoBody-CD3xCD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial
Authors
Hutchings, M.Lugtenburg, P.
Mous, R.
Clausen, M. R.
Chamuleau, M.
Linton, Kim M
Rule, S.
Lopez, J. S.
Oliveri, R. S.
DeMarco, D.
Elliott, B.
Johnson, P.
Affiliation
Rigshospitalet, Copenhagen, DenmarkIssue Date
2020